In September 2014, Gilead Sciences has signed licensing agreements with seven Indian generic manufacturers (Cadila Healthcare Ltd., Cipla Ltd., Hetero Labs Ltd., Mylan Laboratories Ltd., Ranbaxy Laboratories Ltd., Sequent Scientific Ltd., Strides Arcolab Ltd.) who under these agreements can produce and sell generic sofosbuvir and the combination of ledipasvir/sofosbuvir in 91 countries. They can also combine sofosbuvir with other hepatitis treatments.8 The license agreements contain information about sofosbuvir patents.